MedTrace Logo

Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD

NCT06969573 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-05-06

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the impact of inhaled Treprostinil on breathlessness and low exercise capacity in patients living with mild chronic obstructive pulmonary disease. Participants will be asked to:

* Perform lung function and exercise tests
* Have ultrasound of their heart
* Have CT images of their lungs
* Visit the lab on 5 different occasions (plus one visit to the CT imaging clinic)

The researchers will compare the effectiveness and feasibility of inhaled Treprostinil to improve breathlessness upon exertion and exercise capacity

Conditions

  • COPD (Chronic Obstructive Pulmonary Disease)

Interventions

DRUG

Placebo

Participants will breathe placebo (room air) from the Tyvaso Inhalation System Ultrasonic nebulizer

COMBINATION_PRODUCT

Treprostinil Inhalation Solution 36 mcg

Participants will breathe either 36 mcg of Treprostinil from the Tyvaso Inhalation System Ultrasonic nebulizer

COMBINATION_PRODUCT

Treprostinil Inhalation Solution 78 mcg

Participants will breathe either 78 mcg of Treprostinil from the Tyvaso Inhalation System Ultrasonic nebulizer

Sponsors & Collaborators

  • University of Alberta

    lead OTHER

Principal Investigators

  • Michael Stickland · University of Alberta

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-05
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes
FDA Device
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06969573 on ClinicalTrials.gov